ArticleVeterinary research2019
Antiviral activity of itraconazole against type I feline coronavirus infection.
Article in Veterinary research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 60 citations in OpenAlex.
- Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial.EBioMedicine · 2021Trial
- Anti-SARS-CoV-2 Small Molecule Targeting of Oxysterol-Binding Protein (OSBP) Activates Cellular Antiviral Innate Immunity.ACS infectious diseases · 2025Article
- In Vitro Evaluation of Aryl Hydrocarbon Receptor Involvement in Feline Coronavirus Infection.Viruses · 2025Article
- Feline infectious peritonitis: A comprehensive evaluation of clinical manifestations, laboratory diagnosis, and therapeutic approaches.Journal of advanced veterinary and animal research · 2024Article
- Review
- Rottlerin-Liposome Inhibits the Endocytosis of Feline Coronavirus Infection.Veterinary sciences · 2023Article
- Structure-Activity Relationships of Ligand Binding to Oxysterol-Binding Protein (OSBP) and OSBP-Related Protein 4.Journal of medicinal chemistry · 2023Article
- Lipid compartments and lipid metabolism as therapeutic targets against coronavirus.Frontiers in immunology · 2023Review
- In vitro antiviral effects of GS-441524 and itraconazole combination against feline infectious peritonitis virus.Research in veterinary science · 2022Article
- Therapeutic Effects of MutianVeterinary sciences · 2021Article
- The rise in cases of mucormycosis, candidiasis and aspergillosis amidst COVID19.Fungal biology reviews · 2021Review
- Feline Coronavirus Antivirals: A Review.Pathogens (Basel, Switzerland) · 2021Review
- Review
- In vitro activity of itraconazole against SARS-CoV-2.Journal of medical virology · 2021Article
- Triazole, imidazole, and thiazole-based compounds as potential agents against coronavirus.Results in chemistry · 2021Review
- Possible Antiviral Activity of 5-Aminolevulinic Acid in Feline Infectious Peritonitis Virus (Feline Coronavirus) Infection.Frontiers in veterinary science · 2021Article
- Current status on treatment options for feline infectious peritonitis and SARS-CoV-2 positive cats.The veterinary quarterly · 2020Review
- Drawing Comparisons between SARS-CoV-2 and the Animal Coronaviruses.Microorganisms · 2020Review
- Clinical efficacy of combination therapy of itraconazole and prednisolone for treating effusive feline infectious peritonitis.The Journal of veterinary medical science · 2020Article
- Potential COVID-19 therapeutics from a rare disease: weaponizing lipid dysregulation to combat viral infectivity.Journal of lipid research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Feline coronaviruses (FCoVs) are the causative agents of severe systemic disease (feline infectious peritonitis: FIP) in domestic and wild cats. FCoVs have been classified into serotypes I and II. Type I FCoV is the dominant serotype (approximately 70-90%) worldwide. Therefore, it is necessary to provide antiviral agents for type I FCoV infection. In this study, we demonstrated that itraconazole (ICZ), practically used for fungal infections in cats, inhibits the type I FCoV infection. ICZ also exhibited antiviral effect in cells after viral infection, suggesting that ICZ could potentially be used as a therapeutic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.